MX2024013002A - Compuestos activos frente a bromodominios - Google Patents
Compuestos activos frente a bromodominiosInfo
- Publication number
- MX2024013002A MX2024013002A MX2024013002A MX2024013002A MX2024013002A MX 2024013002 A MX2024013002 A MX 2024013002A MX 2024013002 A MX2024013002 A MX 2024013002A MX 2024013002 A MX2024013002 A MX 2024013002A MX 2024013002 A MX2024013002 A MX 2024013002A
- Authority
- MX
- Mexico
- Prior art keywords
- bromodomains
- compounds active
- active towards
- compounds
- towards
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE2250473 | 2022-04-19 | ||
| PCT/US2023/019121 WO2023205251A1 (en) | 2022-04-19 | 2023-04-19 | Compounds active towards bromodomains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024013002A true MX2024013002A (es) | 2024-11-08 |
Family
ID=86331094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013002A MX2024013002A (es) | 2022-04-19 | 2024-10-21 | Compuestos activos frente a bromodominios |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250382308A1 (enExample) |
| EP (1) | EP4511119A1 (enExample) |
| JP (1) | JP2025514712A (enExample) |
| CN (1) | CN119365455A (enExample) |
| AU (1) | AU2023255396A1 (enExample) |
| CA (1) | CA3255932A1 (enExample) |
| MX (1) | MX2024013002A (enExample) |
| WO (1) | WO2023205251A1 (enExample) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8476260B2 (en) | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EP2496580B1 (en) | 2009-11-05 | 2013-12-11 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| SI2496582T1 (sl) | 2009-11-05 | 2016-04-29 | Glaxosmithkline Llc Corporation Service Company | Benzodiazepinski inhibitor bromodomene |
| MX384074B (es) | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| ES2526671T3 (es) | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| US20150344444A1 (en) | 2012-12-20 | 2015-12-03 | Bayer Pharma Aktiengesellschaft | Bet-protein-inhibiting dihydroxyquinoxalinones |
| CN105229002A (zh) | 2012-12-20 | 2016-01-06 | 拜耳医药股份有限公司 | 抑制bet蛋白的二氢吡啶并吡嗪酮 |
| ES2896400T3 (es) | 2014-08-01 | 2022-02-24 | Nuevolution As | Compuestos activos frente a bromdominios |
| CA3048602A1 (en) * | 2016-12-27 | 2018-07-05 | Fujifilm Corporation | Antitumor agent and bromodomain inhibitor |
-
2023
- 2023-04-19 JP JP2024560880A patent/JP2025514712A/ja active Pending
- 2023-04-19 CN CN202380043848.XA patent/CN119365455A/zh active Pending
- 2023-04-19 US US18/860,589 patent/US20250382308A1/en active Pending
- 2023-04-19 CA CA3255932A patent/CA3255932A1/en active Pending
- 2023-04-19 AU AU2023255396A patent/AU2023255396A1/en active Pending
- 2023-04-19 EP EP23723033.9A patent/EP4511119A1/en active Pending
- 2023-04-19 WO PCT/US2023/019121 patent/WO2023205251A1/en not_active Ceased
-
2024
- 2024-10-21 MX MX2024013002A patent/MX2024013002A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250382308A1 (en) | 2025-12-18 |
| EP4511119A1 (en) | 2025-02-26 |
| WO2023205251A1 (en) | 2023-10-26 |
| CN119365455A (zh) | 2025-01-24 |
| CA3255932A1 (en) | 2023-10-26 |
| AU2023255396A1 (en) | 2024-10-24 |
| JP2025514712A (ja) | 2025-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020106647A3 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| ZA202404648B (en) | Azetidine and pyrrolidine parp1 inhibitors and uses thereof | |
| JOP20250258A1 (ar) | مثبطات 2-آزا باي سيكلو هبتان kras | |
| NZ795548A (en) | Allosteric egfr inhibitors and methods of use thereof | |
| MX2020008777A (es) | Inmunoterapias relacionadas con el microbioma. | |
| MX2023009682A (es) | Inhibidores de tyk2 y sus usos. | |
| EP4497438A3 (en) | Tricyclic parp1 inhibitors and uses thereof | |
| MX2023009520A (es) | Compuesto de 4-aminoquinazolina. | |
| MX2023009685A (es) | Inhibidores de tyk2 y sus usos. | |
| MX2025003571A (es) | Inhibidores de tead y metodos de uso de los mismos | |
| WO2022238565A3 (en) | Modulators of sortilin activity | |
| MX2025005941A (es) | Moduladores de la actividad tnf-\03b1 | |
| WO2023205463A8 (en) | Heteroaryl compounds for the treatment of pain | |
| MX2025010397A (es) | Compuestos heterociclicos como inhibidores de la helicasa del sindrome de werner (wrn) | |
| MX2025003515A (es) | Moduladores de akt1 | |
| MX2022015813A (es) | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
| MX2023009723A (es) | Inhibidores de tyk2 y sus usos. | |
| WO2021046315A3 (en) | Inhibitors of encephalitic alphaviruses | |
| MX2023000438A (es) | Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1. | |
| MX2025001990A (es) | Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico | |
| WO2023102162A8 (en) | Novel hdac inhibitors and therapeutic use thereof | |
| MX2025000659A (es) | Compuestos de imidazopiridina, preparacion de los mismos y usos terapeuticos de los mismos | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| MX2025005713A (es) | Moduladores basados en ftalazinona para el tratamiento de enfermedad | |
| MX2023005371A (es) | Moduladores de receptor gamma activado por proliferador de peroxisoma (ppar gamma) y metodos de uso. |